NCT03058822View on ClinicalTrials.gov

Relative Bioavailability of BMS-931699 From Prefilled Syringe Compared to Drug in Vial

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

January 25, 2017

Primary Completion Date

March 30, 2017

Study Completion Date

March 30, 2017

Conditions
Healthy
Interventions
DRUG

BMS-931699

BMS-931699 single subcutaneous dose on Day 1

Trial Locations (1)

33143

Qps-Mra, Llc, South Miami

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY